EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inflamma-miRs Profile in Myelodysplastic Syndrome Patients

Paola Montes iD, Iryna Rusanova iD, Elena Cornejo iD, Paloma García, Ana Guerra-Librero iD, Mª Del Señor López, Tomás de Haro, Germaine Escames iD, Darío Acuña-Castroviejo iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Paola Montes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Biomédica, Departamento de Fisiología, Facultad de Medicina, Instituto de Biotecnología, Parque Tecnológico de Ciencias de la…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, MicroRNAs, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Consejería de Economía, Conocimiento, Empresas y Universidad, European Regional Development Fund/European Social Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Etiological factors involved in myelodysplastic syndrome (MDS) include immunologic, oxidative stress and inflammatory factors, among others, and these are targets for microRNAs (miRNs). Here, we evaluated whether some miRNs may affect tumor development comparing untreated and 5-azacitidine (5-AZA) MDS-treated patients. Peripheral blood samples were collected from 20 controls and 24 MDS patients, and selected miRNs related to redox balance and inflammation (inflamma-miRs), including miR-18a, miR-21, miR-34a and miR-146a, were isolated and measured by quantitative real-time polymerase chain reaction (qRTPCR). A differential expression profile of miRNs was detected in untreated MDS patients and the 5-AZA group. Inflammation increases miRNs and, specifically, miR-18a, miR-21 and miR-34a were significantly overexpressed in untreated MDS, compared to controls. However, we did not observe any miRN profile alteration during the progression of the disease. On the other hand, 5-AZA treatment tends to restore miRN expression levels. Relating to prognostic risk factors, high-risk MDS groups (high Revised International Prognostic Scoring System (IPSS-R), high cytogenetic risk, high molecular risk (HMR) mutations) tended to be related with higher expression levels of miR-18a and miR-34a. Higher miRN expression is correlated with lower glutathione peroxidase activity, while they are related with a higher profile of pro-inflammatory cytokines (IL-2, IL-6, IL-8, TNF-α). Although our study was limited by the low number of MDS patients included, we identified miRN deregulation involved in MDS development that could regulate redox sensors and inflammatory responses. Finally, 5-AZA treatment is related with lower miRN expression levels in MDS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesMicroRNAsInflammationHumansMaleFemaleMiddle AgedAgedAzacitidineAdultAged, 80 and overOxidative StressCase-Control StudiesPrognosis

Stichwörter der Autor:innen

5-azacitidine (5-AZA)inflammatory cytokinesmicroRNAs (miRNs)myelodysplastic syndrome (MDS)oxidative stress

Substanzen

MicroRNAsAzacitidine

Autor:innen und Institutionen

  • Centro de Investigación Biomédica, Departamento de Fisiología, Facultad de Medicina, Instituto de Biotecnología, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, 18016 Granada, Spain.
  • UGC de Laboratorios Clínicos, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.
  • Departamento de Bioquímica y Biología Molecular I, Facultad de Ciencias, Instituto de Biotecnología, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, 18016 Granada, Spain.
  • Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto Biosanitario de Granada (Ibs.Granada), Hospital Universitario San Cecilio, 18016 Granada, Spain.
  • Instituto Biosanitario de Granada (Ibs.Granada), Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.
  • UGC de Hematología y Hemoterapia, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.

ORCID-Profile: Paola Montes, Iryna Rusanova, Elena Cornejo, Ana Guerra-Librero, Germaine Escames, Darío Acuña-Castroviejo

Förderung

  • Instituto de Salud Carlos III
  • Consejería de Economía, Conocimiento, Empresas y Universidad
  • European Regional Development Fund/European Social Fund
  • Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía
  • ISCIII, Spain
  • UGC de Laboratorios Clínicos, Hospital Universitario San Cecilio, Granada, Spain

Zitieren

APA

Montes, P., Rusanova, I., Cornejo, E., García, P., Guerra-Librero, A., López, M. D. S., Haro, T., Escames, G., & Acuña-Castroviejo, D. (2024). Inflamma-miRs Profile in Myelodysplastic Syndrome Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126784

Vancouver

Montes P, Rusanova I, Cornejo E, García P, Guerra-Librero A, López MDS, et al. Inflamma-miRs Profile in Myelodysplastic Syndrome Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126784

BibTeX
@article{Montes2024,
  author = {Montes, Paola and Rusanova, Iryna and Cornejo, Elena and García, Paloma and Guerra-Librero, Ana and López, Mª Del Señor and Haro, Tomás de and Escames, Germaine and Acuña-Castroviejo, Darío},
  title = {Inflamma-miRs Profile in Myelodysplastic Syndrome Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126784}
}
Kostenlos starten →